Pfizer agreed to pay $190 million to settle the gabapentin case

Source: Ding Xiangyuan on April 24, 2014, according to court documents submitted on April 21, Pfizer agreed to pay $190 million to settle a class action lawsuit, which said that Pfizer took measures to delay the listing of its epilepsy drug gabapentin generic Lawyers collectively disclosed the terms of the settlement on behalf of Gaba Martin buyers in a motion The lawsuit, originally filed in 2002, said Pfizer had taken a variety of measures to maintain its gabapentin franchise, including false patent infringement litigation and promotion of the drug's unauthorized use Buyers of gabapentin said Pfizer's actions forced them to pay too much for the drug Pfizer has not acknowledged responsibility or wrongdoing, saying in a statement that the solution "reflects Pfizer's desire to focus on its business and the needs of patients and prescribers, while also reducing costs and avoiding long litigation distractions." "After a long and difficult lawsuit, we are satisfied with the result," said Robert Kaplan, a lawyer for the plaintiff In 2004, Pfizer agreed to pay $430 million to federal and state governments and admitted criminal charges of illegal marketing of gabapentin, acquired by Pfizer when it acquired Warner Lambert in 2000 Original link: http://www.reuters.com/article/2014/04/21/us-usa-antitrust-pfizer-idusbrea3k17420140421